Last reviewed · How we verify
NCT06192927
Efficacy and Safety of TenoMiR in Lateral Epicondylitis
Phase 2 trial testing TenoMiR in Tennis Elbow in 123 participants. Completed in 12 June 2025.
3 March 2025
Quick facts
| Lead sponsor | Causeway Therapeutics |
|---|---|
| Phase | Phase 2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 123 |
| Start date | 10 April 2024 |
| Primary completion | 3 March 2025 |
| Estimated completion | 12 June 2025 |
| Sites | 9 locations across United Kingdom, United States |
Drugs / interventions tested
- TenoMiR — full drug profile →
- 0.9% Sodium Chloride Injection
Conditions studied
- Tennis Elbow — all drugs for Tennis Elbow →
Sponsor
Causeway Therapeutics — full company profile →
Who can join
Adults 18 to 65, any sex, with Tennis Elbow. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is testing a drug called TenoMiR that is being developed for the treatment of tennis elbow (lateral epicondylitis). The study drug is a new compound that works by improving the quality of the collagen which helps repair damage to the elbow. The study drug is being developed in the hope of providing a more reliable treatment than those currently available and can be given at the time of first diagnosis, so that recovery can begin as soon as possible. The study drug has been tested in humans in an earlier study, and appeared to be safe and well-tolerated. This study aims to test the study drug in a larger number of participants.
Publications & conference data
5 peer-reviewed publications reference this trial (live from Europe PMC):
-
Nucleic acid drugs: recent progress and future perspectives.
Sun X, Setrerrahmane S, Li C, Hu J, et al · · 2024 · cited 72× · PMID 39609384 · DOI 10.1038/s41392-024-02035-4 -
Nanoparticles Used for the Delivery of RNAi-Based Therapeutics.
Ren T, Ma L, Fu P, Zhang C. · · 2025 · cited 4× · PMID 41304838 · DOI 10.3390/pharmaceutics17111502 -
Interpretation of the molecular mechanism and therapeutic potential of microRNA‑155 in cardiovascular and cerebrovascular diseases (Review).
Zhao X, Wang P. · · 2026 · cited 2× · PMID 41201055 · DOI 10.3892/ijmm.2025.5681 -
The harmonies played by miR-302/367 cluster in pluripotency, reprogramming, and rejuvenation.
Zamanian M, Moradi S, Baharvand H. · · 2026 · PMID 41693061 · DOI 10.1093/stcltm/szaf072 -
The Hospital for Special Surgery Center for Regenerative Medicine: Clinical Registries, Basic and Translational Research, and Education Programs.
Rodeo SA, de la Huerta Meza D, Kirschner J, Andres Bergos J. · · 2025 · PMID 40678472 · DOI 10.1177/15563316251353511
Verify or expand the search:
- PubMed search for NCT06192927
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Tennis Elbow
Currently open trials in the same condition.
- NCT07406802 — Association Between Racket Stiffness and Lateral Epicondylalgia in Tennis Players · recruiting
- NCT07523893 — Comparative Effects of Shockwave Therapy and Eccentric Exercises in Patients With Lateral Epicondylitis · NA · recruiting
- NCT07342426 — High and Low Dose High-intensity Laser Therapy Lateral Epicondylitis · Phase 4 · recruiting
- NCT07178288 — Assessment of Pressure Pain Threshold (PPT) and Conditioned Pain Modulation (CPM) After Effect in Patients With and With · NA · recruiting
- NCT07043335 — Comparison of the Efficacy of Mesotherapy and Extracorporeal Shock Wave Therapy in Patients With Lateral Epicondylitis · NA · recruiting
Other Causeway Therapeutics trials
Trials by the same sponsor.
- NCT04670289 — Safety, Tolerability, and Pharmacokinetics of Single Dose TenoMiR as a Treatment for Tennis Elbow · Phase 1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06192927 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Causeway Therapeutics
- Last refreshed: 1 August 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06192927.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing